1 active not recruiting, 1 completed. 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 2 | Active not recruiting 1, Completed 1 |
Follow Young-Suk Lim: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effectiveness of TAF in Reducing Clinical Events in CHB Patients Beyond Treatment Indications by Current Guidelines Tenofovir Alafenamide - Chronic Hepatitis b | Phase 4 | Active not recruiting | Young-Suk Lim | 780 | 2019-02-18 | 2024-12-17 |
| Switching From TDF to TAF vs. Maintaining TDF in Chronic Hepatitis B With Resistance to Adefovir or Entecavir. Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate - Chronic Hepatitis b | Phase 4 | Completed | Young-Suk Lim | 174 | 2017-10-26 | 2021-03-29 |
tenofovir alafenamide (2) · Tenofovir (1)
South Korea (2)
PMID 15470215, PMID 16391218, PMID 16530509, PMID 16673294, PMID 19092267, PMID 19207973, PMID 20037275, PMID 20049753, PMID 21374657, PMID 25596179, PMID 25800784, PMID 28404091, PMID 28404092, PMID 33962041, PMID 39914435